, Volume 71, Issue 1–2, pp 79–84 | Cite as

Retention Behaviour of Bupropion Hydrochloride in Reversed Phase Ion Pair LC and Validated Analysis of the Drug in Pharmaceuticals

Full Short Communication


The chromatographic behaviour of bupropion hydrochloride, a basic drug of pK a 7.9, has been investigated under reversed-phase ion-pairing conditions and the results were used to develop a method for analysis of bupropion hydrochloride in pharmaceuticals. Chromatographic separation of bupropion hydrochloride and carbamazepine (used as internal standard) was performed on a C8 column (150 mm × 4.6 mm i.d., 3.5-μm particle), with 40:10:50 (v/v) methanol–acetonitrile–phosphate buffer (20 mm, pH 3.0), containing 10 mm 1-heptane sulfonic acid sodium salt (1-HSA), as optimum mobile phase at a flow rate of 1.0 mL min−1. UV detection was at 254 nm. The fully validated method enables reproducible and selective analysis of bupropion hydrochloride in pharmaceuticals.


Column liquid chromatography Ion-pairing Pharmaceutical analysis Method validation Bupropion hydrochloride 



The authors are grateful to the Research Council of Anadolu University for support of this project (project no: 060324), to GlaxoSmithKline (Istanbul, Turkey) for the gift sample of BUP standard, and to Professor Dr Muzaffer Tuncel for his valuable help in all the authors’ studies. DY acknowledges a scholarship for PhD students from the Scientific and Technical Research Council of Turkey (TUBITAK).


  1. 1.
    Richmond R, Zwar N (2003) Drug Alcohol Rev 22:203–220CrossRefGoogle Scholar
  2. 2.
    Loboz KK, Gross AS, Ray J, McLachlan AJ (2005) J Chromatogr B 823:115–121CrossRefGoogle Scholar
  3. 3.
    Zhang D, Yuan B, Qiao M, Li F (2003) J Pharm Biomed Anal 33:287–293CrossRefGoogle Scholar
  4. 4.
    Cooper TB, Suckow RF, Glassman A (1984) J Pharm Sci 73:1104–1107CrossRefGoogle Scholar
  5. 5.
    Suckow RF, Zhang MF, Cooper TB (1997) Biomed Chromatogr 11:174–179CrossRefGoogle Scholar
  6. 6.
    Jennison TA, Brown P, Crossett J, Urry FM (1995) J Anal Toxicol 19:69–72Google Scholar
  7. 7.
    Borges V, Yang E, Dunn J, Henion J (2004) J Chromatogr B 804:277–287CrossRefGoogle Scholar
  8. 8.
    Coles R, Kharasch ED (2007) J Chromatogr B 857:67–75CrossRefGoogle Scholar
  9. 9.
    Munro JS, Walker TA (2001) J Chromatogr A 913:275–282CrossRefGoogle Scholar
  10. 10.
    Munro JS, Gormley JP, Walker TA (2001) J Liq Chromatogr Relat Technol 24:327–339CrossRefGoogle Scholar
  11. 11.
    Castro-Puyana M, Garcia MA, Marina ML (2008) J Chromatogr B 875:260–265CrossRefGoogle Scholar
  12. 12.
    Laizure SC, DeVane CL (1985) Ther Drug Monit 7:447–450CrossRefGoogle Scholar
  13. 13.
    Suckow RF, Smith TM, Perumal AS, Cooper TB (1986) Drug Metab Dispos 14:692–697Google Scholar
  14. 14.
    The United States Pharmacopeia (2006) USP-29, Marck Printing, Easton, pp 320–324Google Scholar
  15. 15.
    ICH Steering Committee (2005) Validation of analytical procedures: text and methodology Q2(R1), harmonized tripartite guidelineGoogle Scholar
  16. 16.
    Shabir GA (2003) J Chromatogr A 987:57–66CrossRefGoogle Scholar
  17. 17.
    Snyder LR, Kirkland JJ, Glajch JL (1997) Practical LC method development. Wiley, New YorkGoogle Scholar
  18. 18.
    Ciolino LA, Turner JA, McCauley HA, Smallwood AW, Yi TY (1999) J Chromatogr A 852:451–463CrossRefGoogle Scholar
  19. 19.
    Başcı NE, Temizer A, Bozkurt A, Isimer A (1998) J Pharm Biomed Anal 18:745–750CrossRefGoogle Scholar
  20. 20.
    Dejaegher B, Vander Heyden Y (2007) J Chromatogr A 1158:138–157CrossRefGoogle Scholar

Copyright information

© Vieweg+Teubner | GWV Fachverlage GmbH 2009

Authors and Affiliations

  1. 1.Department of Analytical Chemistry, Faculty of PharmacyAnadolu UniversityEskisehirTurkey

Personalised recommendations